Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT: 2010-2021

Historic EBIT for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $44.5 million.

  • Neurocrine Biosciences' EBIT rose 200.45% to $44.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $94.5 million, marking a year-over-year decrease of 32.49%. This contributed to the annual value of $72.3 million for FY2019, which is 95.92% up from last year.
  • Neurocrine Biosciences' EBIT amounted to $44.5 million in Q3 2021, which was down 29.14% from $62.8 million recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' EBIT registered a high of $90.1 million during Q3 2019, and its lowest value of -$101.0 million during Q1 2019.
  • Moreover, its 3-year median value for EBIT was $46.6 million (2019), whereas its average is $30.2 million.
  • In the last 5 years, Neurocrine Biosciences' EBIT plummeted by 283.24% in 2017 and then skyrocketed by 1,957.45% in 2019.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' EBIT stood at $11.8 million in 2017, then soared by 84.81% to $21.9 million in 2018, then spiked by 123.05% to $48.8 million in 2019, then crashed by 149.17% to -$44.3 million in 2020, then skyrocketed by 200.45% to $44.5 million in 2021.
  • Its last three reported values are $44.5 million in Q3 2021, $62.8 million for Q2 2021, and $31.5 million during Q1 2021.